Evrópusambandið - enska - EMA (European Medicines Agency)

zoetis belgium sa - canine distemper virus, strain cdv bio 11/a, canine adenovirus type 2, strain cav-2 bio 13, canine parvovirus type 2b, strain cpv-2b bio 12/b and canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (all live attenuated) - immunologicals for canidae, live viral vaccines - dogs - active immunisation of dogs from six weeks of age.to prevent mortality and clinical signs caused by canine distemper virus,to prevent mortality and clinical signs caused by canine adenovirus type 1,to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus,to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus.

Evrópusambandið - enska - EMA (European Medicines Agency)

zoetis belgium sa - canine parainfluenza type-2 virus, strain cpiv-2 bio 15 (live attenuated) - immunologicals for canidae, live viral vaccines - dogs - active immunisation of dogs from six weeks of age to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus.

Evrópusambandið - enska - EMA (European Medicines Agency)

zoetis belgium sa. - canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090 and l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091 (all inactivated) - immunologicals for canidae, live viral and inactivated bacterial vaccines - dogs - active immunisation of dogs from six weeks of age. - to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus, - to prevent clinical signs, infection and urinary excretion caused by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae. onset of immunity: immunity has been demonstrated from 3 weeks after completion of the primary course for cpiv and from 4 weeks after completion of the primary course for leptospira components. duration of immunity: at least one year following the primary vaccination course for all components of versican plus pi/l4.

Bandaríkin - enska - NLM (National Library of Medicine)

merck sharp & dohme llc - measles virus strain enders' attenuated edmonston live antigen (unii: mfz8i7277d) (measles virus strain enders' attenuated edmonston live antigen - unii:mfz8i7277d), mumps virus strain b level jeryl lynn live antigen (unii: 47qb6mx9ku) (mumps virus strain b level jeryl lynn live antigen - unii:47qb6mx9ku), rubella virus strain wistar ra 27/3 live antigen (unii: 52202h034z) (rubella virus strain wistar ra 27/3 live antigen - unii:52202h034z), varicella-zoster virus strain oka/merck live antigen (unii: gpv - measles virus strain enders' attenuated edmonston live antigen 1000 [tcid_50] in 0.5 ml - proquad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age. do not administer proquad to individuals with a history of hypersensitivity to any component of the vaccine (including gelatin) {1} or to a previous dose of m-m-r ii (measles, mumps, rubella, live), proquad or varivax (varicella virus vaccine live) vaccine, or any other measles, mumps, and rubella or varicella-containing vaccine. do not administer proquad to individuals with a history of anaphylaxis to neomycin [see description (11)] . do not administer proquad vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. measles inclusion body encephalitis {2} (mibe), pneumonitis {3} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. in this population, disseminated mump

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - human rotavirus rix4414 strain live attenuated - oral suspension

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - human rotavirus rix4414 strain live attenuated - oral suspension

Írland - enska - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - infectious bursal disease virus strain lukert - lyophilisate for oculonasal suspension/use in drinking water - tissue culture infective dose 50/dose - avian infectious bursal disease virus (gumboro disease) - chickens - immunological - live vaccine

Írland - enska - HPRA (Health Products Regulatory Authority)

ceva-phylaxia veterinary biologicals co. ltd - avian infectious bursal disease virus, live - concentrate and solvent for suspension for injection - . - avian infectious bursal disease virus (gumboro disease)

Evrópusambandið - enska - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccines - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).the use of dengvaxia should be in accordance with official recommendations.

Írland - enska - HPRA (Health Products Regulatory Authority)

genera inc - avian infectious bursal disease virus, live - lyophilisate for oculonasal suspension/use in drinking water - . - avian infectious bursal disease virus (gumboro disease)